drugset / Trial / NCT07105488
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Timeline
- Start
- 2025-07-15
- Primary completion
- 2027-02-28
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BFB759 | Monoclonal antibody | — | — |